Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises-Reference-Cited by-同舟云学术

Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises

Published:2024-04-09 Issue:8 Volume:67 Page:6052-6063
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Pervanidis Kosmas Alexandros¹^ORCID,D’Angelo Giovanni Danilo¹,Weisner Jörn¹²^ORCID,Brandherm Sven¹²,Rauh Daniel¹^ORCID

Affiliation:

1. Department of Chemistry and Chemical Biology, TU Dortmund University and Drug Discovery Hub Dortmund (DDHD), Zentrum für Integrierte Wirkstoffforschung (ZIW), Otto-Hahn-Strasse 4a, 44227 Dortmund, Germany

2. KyDo Therapeutics, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany

Funder

Bundesministerium f?r Bildung und Forschung

European Regional Development Fund

Deutsche Forschungsgemeinschaft

Land Nordrhein-Westfalen

Ministerium f?r Kultur und Wissenschaft des Landes Nordrhein-Westfalen

Mercator Research Center Ruhr

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00075

Reference65 articles.

1. New Insights into Protein Kinase B/Akt Signaling: Role of Localized Akt Activation and Compartment-Specific Target Proteins for the Cellular Radiation Response

2. AKT/PKB Signaling: Navigating the Network

3. Defective insulin secretion and increased susceptibility to experimental diabetes are induced by reduced Akt activity in pancreatic islet β cells

4. The structural basis of Akt PH domain interaction with calmodulin

5. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elucidation of the solution structure of macrocyclic paritaprevir and exploration of its antitumor potential through molecular docking;Journal of Molecular Liquids;2024-09